A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Insulin degludec/liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 01 Sep 2017 Status changed from not yet recruiting to discontinued.
- 25 Apr 2017 Planned End Date changed from 15 Apr 2019 to 16 Aug 2019.